AR and cancer: The first small molecule-based PROTAC with a non-steroidal AR ligand as a target protein ligand and nutlin as an E3 ligase ligand via a PEG-based linker (Figure 7), reported in 2008, effectively degraded AR after cell membrane permeation in cancer cells [24].